K
Kiyoshi Takasugi
Researcher at Yale University
Publications - 28
Citations - 1234
Kiyoshi Takasugi is an academic researcher from Yale University. The author has contributed to research in topics: Tocilizumab & Arthritis. The author has an hindex of 17, co-authored 28 publications receiving 1106 citations.
Papers
More filters
Journal ArticleDOI
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population
Yukinori Okada,Chikashi Terao,Katsunori Ikari,Yuta Kochi,Koichiro Ohmura,Akari Suzuki,Takahisa Kawaguchi,Eli A. Stahl,Eli A. Stahl,Fina A S Kurreeman,Fina A S Kurreeman,Fina A S Kurreeman,Nao Nishida,Hiroko Ohmiya,Keiko Myouzen,Meiko Takahashi,Tetsuji Sawada,Yuichi Nishioka,Masao Yukioka,Tsukasa Matsubara,Shigeyuki Wakitani,Ryota Teshima,Shigeto Tohma,Kiyoshi Takasugi,Kota Shimada,Akira Murasawa,Shigeru Honjo,Keitaro Matsuo,Hideo Tanaka,Kazuo Tajima,Taku Suzuki,Takuji Iwamoto,Yoshiya Kawamura,Hisashi Tanii,Yuji Okazaki,Tsukasa Sasaki,Peter K. Gregersen,Leonid Padyukov,Jane Worthington,Katherine A. Siminovitch,Mark Lathrop,Atsuo Taniguchi,Atsushi Takahashi,Katsushi Tokunaga,Michiaki Kubo,Yusuke Nakamura,Naoyuki Kamatani,Tsuneyo Mimori,Robert M. Plenge,Robert M. Plenge,Hisashi Yamanaka,Shigeki Momohara,Ryo Yamada,Fumihiko Matsuda,Kazuhiko Yamamoto +54 more
TL;DR: This study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10−8, including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.
Journal ArticleDOI
Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.
Yasuaki Okuda,Kiyoshi Takasugi +1 more
TL;DR: Tocilizumab appears to have an excellent ability to suppress SAA levels and could therefore be an important therapeutic strategy in AA amyloidosis secondary to rheumatic diseases.
Journal ArticleDOI
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Norihiro Nishimoto,Norihiro Nishimoto,Koichi Amano,Yasuhiko Hirabayashi,Takahiko Horiuchi,Tomonori Ishii,Mitsuhiro Iwahashi,Masahiro Iwamoto,Hitoshi Kohsaka,Masakazu Kondo,Tsukasa Matsubara,Toshihide Mimura,Hisaaki Miyahara,Shuji Ohta,Yukihiko Saeki,Kazuyoshi Saito,Hajime Sano,Kiyoshi Takasugi,Tsutomu Takeuchi,Shigeto Tohma,Tomomi Tsuru,Yukitaka Ueki,Jiro Yamana,Jun Hashimoto,Takaji Matsutani,Miho Murakami,Miho Murakami,Nobuhiro Takagi +27 more
TL;DR: TCZ monotherapy may induce biologics-free remission or LDA without concomitant use of synthetic DMARDs and Serum levels of IL-6 and MMP-3 are useful markers for identifying patients who could discontinue TCZ without acute disease flare.
Journal ArticleDOI
Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis
Koichiro Ohmura,Chikashi Terao,Etsuko Maruya,Masaki Katayama,Kenichiro Matoba,Kota Shimada,Akira Murasawa,Shigeru Honjo,Kiyoshi Takasugi,Shigeto Tohma,Keitaro Matsuo,Kazuo Tajima,Naoichiro Yukawa,Daisuke Kawabata,Takaki Nojima,Takao Fujii,Ryo Yamada,Hiroo Saji,Fumihiko Matsuda,Tsuneyo Mimori +19 more
TL;DR: ACPA-negative erosive RA is genetically distinct from ACPA-positive RA, suggesting that the subsets distinguished by ACPA are not based simply on differences in autoantibody production.
Journal ArticleDOI
Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases
Yasuaki Okuda,Makoto Ohnishi,Kenichiro Matoba,Kazuo Jouyama,Akihiro Yamada,Naoya Sawada,Sho Mokuda,Yousuke Murata,Kiyoshi Takasugi +8 more
TL;DR: It is concluded that tocilizumab (TCZ) was of greater clinical utility than anti-TNF therapy in patients with AA amyloidosis complicating rheumatic diseases.